Every 8-K that Utah Medical Products Inc (UTMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow UTMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UTMD filings page.
Utah Medical Products, Inc. (UTMD) reported that its wholly owned subsidiary Femcare Ltd has purchased all of the common shares of UK-based Orion Medical Supplies Ltd, a niche assembler and distributor of Harm Reduction medical device kits primarily in the UK and Europe. Orion’s products are used in programs aimed at reducing blood borne infections, harmful drug litter, overdose injuries and deaths, and related social impacts among drug users.
UTMD states that Orion is a stable, profitable business expected to be accretive to financial results, adding about $6 million to current consolidated annual sales, with potential for geographic expansion. The purchase price was £3.6 million, paid from cash reserves. Orion’s operations will be moved into Femcare’s existing Romsey facilities to leverage existing infrastructure and dilute overhead as a percentage of UK sales. UTMD notes that outcomes are subject to forward‑looking risks, and additional acquisition-related risk factors will appear in its third quarter 2026 Form 10‑Q, expected to be filed by October 15.
Utah Medical Products reported weaker results for the quarter and first half ended June 30, 2026. Second‑quarter net sales were $8,529, down 14.3% from 2025, and first‑half sales were $17,252, down 12.3%, mainly from the loss of two large customers whose 2025 sales totaled $2,889. New biopharma OEM sales reached only $211 in 1H 2026. Net income was $2,686 in 2Q and $5,290 in 1H, declines of 11.9% and 13.1%, with diluted EPS of $0.844 and $1.661 respectively.
Despite lower volumes and higher U.S. litigation costs, profitability remained high: gross margin was 55.8% in 2Q and 58.2% in 1H, and adjusted EBITDA margin was 43.9% for 1H. Management now projects 2026 sales to fall 10–13% versus 2025 and expects 2026 litigation expense to remain below $1.6 million. The balance sheet stayed strong with $87,528 in cash and investments, no debt, a 48.6 current ratio, ongoing dividends equal to 37% of year‑to‑date net income, and modest share repurchases.
Utah Medical Products, Inc. reported the results of its annual stockholder meeting held on May 1, 2026. Stockholders elected Ernst G. Hoyer and James H. Beeson as directors, with Beeson receiving 1,708,941 votes for and Hoyer 1,330,333 votes for, alongside broker non-votes on each proposal.
Stockholders also ratified the selection of Haynie & Co. as the company’s independent public accounting firm for the year ended December 31, 2026, with 2,753,278 votes for. On an advisory basis, stockholders approved the compensation of the company’s named executive officers, with 2,354,919 votes for. The company plans to continue holding annual advisory votes on executive compensation until at least the next required vote on the frequency of these votes.
Utah Medical Products reported Q1 2026 results with net sales of $8.7 million, down 10.2% from Q1 2025. Net income declined 14.4% to $2.6 million, while earnings per share fell 11.0% to $0.818. Despite lower revenue, the company’s gross margin improved to 60.6% from 57.0%, reflecting a more profitable product mix and cost adjustments.
Operating income decreased 18.7% to $2.6 million as higher general and administrative costs, including litigation and health care expenses, weighed on results. The balance sheet remained debt-free, with cash and investments rising to $87.4 million and stockholders’ equity increasing to $120.4 million.
Utah Medical Products, Inc. furnished an update on its business by providing financial information for the three and twelve months ended December 31, 2025, in a press release dated January 29, 2026. The press release, attached as Exhibit 99.1, also contains forward-looking statements about 2025 and beyond.
The company submitted this information under a current report, stating that the material is being furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings.
Utah Medical Products (UTMD) expanded its Board from five to six members and appointed Kevin Timken as a director. He will serve on the Audit Committee and the Compensation and Benefits Committee. Timken previously advised UTMD on U.S. SEC matters during a 25-year legal career.
As a director, Timken received 10,000 stock options with an exercise price of $58.10 per share, vesting over four years, and the standard Board fee of $7,650 per quarter, pro‑rated for the final quarter of 2025.
UTMD also increased its regular quarterly cash dividend to $0.31 per share, payable on January 5, 2026 to shareholders of record at the close of business on December 16, 2025.
Utah Medical Products, Inc. furnished an update on its results under Item 2.02. The company attached a press release (Exhibit 99.1) with financial information for the three and nine months ended September 30, 2025, along with forward-looking statements for 2025 and beyond.
The information was furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings.